NasdaqCM:UNCYBiotechs
Why Unicycive Therapeutics (UNCY) Is Down 19.6% After FDA CRL Over Third-Party Manufacturing Issues And What's Next
Unicycive Therapeutics recently disclosed that the FDA issued another Complete Response Letter for its resubmitted New Drug Application for oxylanthanum carbonate, citing unresolved deficiencies at a third-party manufacturing vendor but raising no new safety or efficacy concerns and requesting no additional clinical data.
This outcome underscores how non-clinical factors such as manufacturing compliance and vendor inspections can critically influence the regulatory path of a late-stage...